- Sputnik International
Get the latest news from around the world, live coverage, off-beat stories, features and analysis.

Encouraged by Frank Discussion Credit Suisse ‘Increasingly Positive’ About Russian Sputnik V Vaccine

© REUTERS / Arnd Wiegmann A national flag of Switzerland flies in front of a branch office of Swiss bank Credit Suisse in Luzern October 30, 2014
A national flag of Switzerland flies in front of a branch office of Swiss bank Credit Suisse in Luzern October 30, 2014 - Sputnik International
MOSCOW (Sputnik) - The research team of Credit Suisse, one of Switzerland’s leading banks, has commended the frank discussion that the developers of the Russian Sputnik V vaccine recently had on its efficacy.

"We were encouraged by the frank discussion of the human viral vector technology used and we view the 92 percent efficacy as a positive incremental readacross for the AstraZeneca data expected soon (possibly early December). However we would note that AZN uses a chimp adenovirus vector vs Sputnik that uses two different human adenovirus vectors", Credit Suisse said in a press release titled "Increasingly positive on Sputnik V COVID-19 vaccine" after observing the call between the Russian Gamaleya Institute and RDIF.

The bank’s research team has noted that the participants in the call addressed the concerns about Russia’s speedy development of the vaccine.

"The discussant pointed to Russia regulation allowing for early approval of drugs during epidemics if based on previously efficient platforms and if they have been through P2 trials", the press release read.

The EpiVacCorona vaccine developed by the Vector centre of the Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being (Rospotrebnadzor) - Sputnik International
Kremlin Trusts Virology Experts' Opinion About Efficiency of Russian COVID-19 Vaccines
Earlier in the week, the Russian Direct Investment Fund (RDIF) announced that Sputnik V vaccine had demonstrated 92 percent efficacy based on the first interim analysis, obtained 21 days after volunteers received the first injection.

Sputnik V, which has been developed by the Gamaleya centre and produced in cooperation with the RDIF, became the world's first registered vaccine against COVID-19 when it was registered by the Russian Ministry of Health on 11 August. Many foreign countries have already ordered Sputnik V from Russia or expressed interest in purchasing the vaccine.

To participate in the discussion
log in or register
Заголовок открываемого материала